Literature DB >> 19481767

Adiponectin deficiency promotes the production of inflammatory mediators while severely exacerbating hepatic injury in mice with polymicrobial sepsis.

Yoshitaka Uji1, Hiroshi Yamamoto, Kazuhisa Maeda, Hiroshi Tsuchihashi, Hiroya Akabori, Tomoharu Shimizu, Yoshihiro Endo, Iichiro Shimomura, Tohru Tani.   

Abstract

BACKGROUND: Adiponectin (APN), which is an adipose tissue-derived hormone, is known as an anti-inflammatory cytokine. The effects of APN on the production of inflammatory mediators and hepatic injury during polymicrobial sepsis were evaluated using APN-knockout (KO) mice that had undergone a cecal ligation and puncture (CLP) and rosiglitazone, a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, which increases the plasma APN concentration.
MATERIALS AND METHODS: Wild type (WT) and APN-KO mice were underwent CLP. The plasma and hepatic levels of inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), were measured before, at 24, and 48 h after CLP. A histological analysis of the liver and the plasma alanine aminotransferase (ALT) levels were examined to evaluate hepatic injury. The plasma levels of inflammatory mediators after CLP with pretreatment of rosiglitazone were compared with those without rosiglitazone.
RESULTS: APN deficiency resulted in significant increases in the plasma levels of TNF-alpha, IL-6, and MCP-1 at 24 h after CLP. Hepatic MCP-1 and plasma AST levels in APN-KO mice were significantly higher than those in WT mice at 48 h after CLP. A steatosis change and MCP-1 expressions in hepatocytes were induced in APN-KO mice during sepsis. The administration of rosiglitazone significantly lowered the plasma levels of inflammatory mediators, including TNF-alpha, IL-6, and MCP-1, in WT mice but not in APN-KO mice during sepsis.
CONCLUSION: These results suggest that an APN deficiency induces an excessive systemic inflammatory status and exacerbates hepatic injury during polymicrobial sepsis. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481767     DOI: 10.1016/j.jss.2008.12.021

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Exogenous recombinant adiponectin improves survival in experimental abdominal sepsis.

Authors:  Bülent Salman; Tonguç Utku Yılmaz; Tugan Tezcaner; Ebru Ofluoğlu Demir; Ozge Tuğçe Paşaoğlu
Journal:  Balkan Med J       Date:  2014-09-01       Impact factor: 2.021

Review 2.  Adiponectin in pulmonary disease and critically ill patients.

Authors:  P Garcia; A Sood
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 3.  Animal models of nonalcoholic fatty liver disease.

Authors:  Lionel Hebbard; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-30       Impact factor: 46.802

Review 4.  Clinical review: adiponectin biology and its role in inflammation and critical illness.

Authors:  Katherine Robinson; John Prins; Bala Venkatesh
Journal:  Crit Care       Date:  2011-04-20       Impact factor: 9.097

5.  Advances in sepsis-associated liver dysfunction.

Authors:  Dawei Wang; Yimei Yin; Yongming Yao
Journal:  Burns Trauma       Date:  2014-07-28

6.  Changes in Plasma Adiponectin Concentrations in Patients With Hemorrhagic Fever With Renal Syndrome: An Observational Prospective Study.

Authors:  Hong Du; Xuefan Bai; Jianqi Lian; Jing Li; Ying Zhang; Pingzhong Wang; Hong Jiang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.